WO1992004332A1 - Imidazole derivatives, their preparation and pharmaceutical compositions - Google Patents

Imidazole derivatives, their preparation and pharmaceutical compositions Download PDF

Info

Publication number
WO1992004332A1
WO1992004332A1 PCT/GB1991/001544 GB9101544W WO9204332A1 WO 1992004332 A1 WO1992004332 A1 WO 1992004332A1 GB 9101544 W GB9101544 W GB 9101544W WO 9204332 A1 WO9204332 A1 WO 9204332A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
pharmaceutically acceptable
compounds
compound
acceptable salt
Prior art date
Application number
PCT/GB1991/001544
Other languages
French (fr)
Inventor
Deirdre Mary Bernadette Hickey
David Gwynn Cooper
Albert Andrzej Jaxa-Chamiec
Original Assignee
Smith Kline & French Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline & French Laboratories Limited filed Critical Smith Kline & French Laboratories Limited
Publication of WO1992004332A1 publication Critical patent/WO1992004332A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • the present invention relates to novel substituted imidazole compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  • the present invention therefore provides in a irst aspect compounds of structure (I) :
  • each group Ar is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl;
  • R 1 is hydrogen, C- ⁇ alkyl, optionally substituted phenyl or optionally substituted heteroaryl;
  • Y is oxygen or sulphur;
  • n is 4 to 12; and
  • X is 5-tetrazolyl, S0 3 H, P(0) (0R) 2 , P(0) (0H) 2 , or
  • R is hydrogen or C 1 _ 4 alkyl, or a pharmaceutically acceptable salt thereof.
  • each group Ar is the same and is optionally substituted phenyl or optionally substituted heteroaryl. More suitably, each group Ar is the same and is optionally substituted phenyl. Preferably each group Ar is the same and is unsubstituted phenyl.
  • R 1 is hydrogen, C 1- alkyl, optionally substituted phenyl or optionally substituted heteroaryl.
  • R 1 is optionally substituted phenyl; most preferably unsubstituted phenyl.
  • Y is oxygen or sulphur; preferably Y is oxygen.
  • n is 4 to 12; preferably n is 4 to 8, most preferably n is 6 or 7.
  • X is 5-tetrazolyl, S0 3 H, P(0) (0R) 2 , P(0) (OH) 2 or P(0) (R) (OR) in which R is hydrogen or c 1- _ 4 alkyl.
  • R is hydrogen or c 1- _ 4 alkyl.
  • X is S0 3 H.
  • Suitable substituents for phenyl groups Ar and R 1 include, for example, 1-3 groups which may be the same or different and are selected from 1 _ 4 alkyl, haloC 1 _ 4 alkyl such as CF 3 , halogen, hydroxy and C 1 _ 4 alkoxy.
  • Suitable heteroaryl groups include, for example, saturated or unsaturated 5- or 6-membered rings comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur.
  • Preferred such rings include, for example, thienyl and furyl rings.
  • Particularly preferred compounds of structure (I) include: sodium 6-(1,4,5-triphenylimidazol-2-yloxy)hexane- sulphonate; sodium 7-(l,4,5-triphenylimidazol-2-yloxy)heptane- sulphonate; 7-(1,4,5-triphenylimidazol-2-yloxy)heptanemethyl- phosphinate; and 7-(1,4 ,5-triphenylimidazol-2-yloxy)heptanephosphonate.
  • the compounds of structure (I) can be prepared using procedures analogous to those known in the art.
  • the present invention therefore provides in a further aspect a process for the preparation of compounds of structure (I) in which X is other than 5-tetrazolyl which comprises reaction of a compound of structure (II) :
  • R 1 , Y and n are as described for structure (I) and L is a leaving group, with a suitable source of the group X; and optionally thereafter forming a pharmaceutically acceptable salt thereof.
  • Compounds of structure (I) in which X is 5-tetrazolyl can be prepared from compounds of structure (II) by standard techniques, for example, when L is bromine, by reaction with sodium cyanide in a suitable solvent such as dimethylsulphoxide , to form the intermediate compound in which L is cyano; followed by reaction with tri-n-butyl tin azide in, for example, tetrahydrofuran to form the desired compound of structure (I) .
  • Suitable leaving groups L will be apparent to those skilled in the art and include, for example, halogen, such as bromine.
  • Suitable sources of the group X will again be apparent to those skilled in the art and include, for example, where X is S0 3 Na, sodium sulphite.
  • the reaction between the compounds of structure (II) and the source of X is carried out in a solvent at elevated temperature.
  • X is S0 3 Na
  • the reaction is carried out in aqueous ethanol at reflux temperature for a suitable period to allow the reaction to go to completion; and where X is a phosphorus containing group the reaction is carried out in an organic solvent such as toluene or xylene.
  • the compounds of structure (II) can be prepared from compounds of structure (III) :
  • Ar, Y and R 1 are as described for structure (I) by reaction with, for example, a compound of formula L 1 (CH 2 ) n L, in which L and L 1 are suitable leaving groups, in the presence of a base such as potassium carbonate and a suitable solvent such as butanone.
  • Suitable groups L are as described for structure (II) .
  • Suitable groups L 1 will be apparent to those skilled in the art, and include halogen, in particular bromine.
  • the compounds of structure (I) and their pharmaceutically acceptable salts have been found to be PGI 2 agonists and as such are useful in therapy for the treatment of disease conditions in which such an effect is beneficial. More specifically, the compounds are expected to have utility as antithrombotic, vasodilatory, anti- atherosclerotic, antiinflammatory and cytoprotective agents. In particular, as antithrombotic and vasodilatory agents, the compounds are expected to be useful in the treatment of cardiovascular occlusive disorders including spasmodic and thrombotic disorders; coronary heart disease (primary and secondary prevention) ; stroke; post-operative thrombosis utilisation including post-angioplasty; deep vein thrombosis; peripheral vascular disease and Reynaud's disease.
  • the compounds would be expected to reduce atherosclerotic plaque formation; and as cytoprotective agents the compounds would be expected to protect liver and gastric mucosa, protect against mucosal and ulcerative damage and reduce infarct size in myocardial infarct.
  • the compounds have antihyperlipidaemic properties and as such are expected to be of use as lipid lowering agents, and in the treatment of atherosclerosis and its sequelae.
  • the compounds of the present invention are usually administered in a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • the compounds of structure (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s) , for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a typical suppository formulation comprises a compound of structure (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
  • composition is in unit dose form such as a tablet or capsule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the present invention also provides a method of mimicking the effects of PGI 2 which comprises administering to a mammal in need thereof an effective amount of a compound of the structure (I) or a pharmaceutically acceptable salt thereof; and a method of treatment of cardiovascular disorders which comprises administering to a mammal in need thereof an effective amount of a compound of the structure (I) or a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen.
  • a daily dosage regimen for an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous , or intramuscular dose of between 0.1 mg and 100 g, preferably between 0.1 mg and 25 mg, of the compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • Platelets were prepared from freshly drawn human blood. Blood was collected into acid citrate anticoagulant, centrifuged (5 min at 500g) , and the upper layer of platelet-rich plasma was removed. This platelet-rich plasma was incubated with aspirin (lOOuM) for 10 min at 37°C and then centrifuged (15 min at 200g) . The platelet pellet was resuspended (at approx.
  • test compound or 0.1% DMSO vehicle was added 2 min before the aggregatory stimulus (l ⁇ M U46619) .
  • the extent of aggregation was assessed 4 min after addition of the stimulus, and was calculated as % of the control response in the absence of test compound. Dose-response curves were constructed for measurement of IC 50 values for each compound.
  • Membranes were prepared from outdated platelet-rich plasma concentrates obtained from the Blood Transfusion Service. The platelets were homogenised in buffer containing Tris-Cl (5mM, pH 7.4 at 20°C) and EDTA (0.25mM), and then centrifuged (10 min at 26,000g). The membrane pellet was washed twice by homogenisation in buffer containing Tris-Cl (50mM, pH 7.4 at 20°C) and EDTA (0.25 mM) , followed by centrifugation.
  • Tris-Cl Tris-Cl
  • EDTA 0.25mM
  • membranes For measurement of [ 3 H]iloprost binding, membranes (0.4-0.8mg) were incubated in the presence of Tris-Cl (50mM, pH 7.4 at 20°C) , MgCl 2 (4mM) , EDTA (40 ⁇ M) , [ 3 H]iloprost (10nM) , DMSO (1.85%), and varying concentrations of the test compounds. For determination of non-specific binding, 20 ⁇ M iloprost was included. The tubes (triplicates for each condition) were set up on ice, and then incubated for 30 min at 37°C. The incubations were terminated by rapid filtration on Whatman GF/B filters using a Brandel Harvester. The filters were washed and then counted for radioactivity. The K ⁇ of the test compounds for inhibition of binding of [ 3 H]iloprost to human platelet membranes was calculated from the IC 50 for displacement of [ 3 H]iloprost binding.

Abstract

Substituted 4,5-diaryl-2-alkoxyimidazoles of structure (I), in which each group Ar is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl; R1 is hydrogen, alkyl, optionally substituted phenyl or optionally substituted heteroaryl; Y is oxygen or sulphur; n is 4 to 12; and X is 5-tetrazolyl, SO¿3?H, P(O)(OR)2, P(O)(OH)2, or P(O)(R)(OR) in which R is hydrogen or alkyl, or a pharmaceutically acceptable salt thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, inter alia, in the treatment of cardiovascular disorders.

Description

IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
The present invention relates to novel substituted imidazole compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
The present invention therefore provides in a irst aspect compounds of structure (I) :
Figure imgf000003_0001
in which each group Ar is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl; R1 is hydrogen, C-^^alkyl, optionally substituted phenyl or optionally substituted heteroaryl; Y is oxygen or sulphur; n is 4 to 12; and X is 5-tetrazolyl, S03H, P(0) (0R)2, P(0) (0H)2, or
P(O) (R) (OR) in which R is hydrogen or C1_4alkyl, or a pharmaceutically acceptable salt thereof.
Suitably, each group Ar is the same and is optionally substituted phenyl or optionally substituted heteroaryl. More suitably, each group Ar is the same and is optionally substituted phenyl. Preferably each group Ar is the same and is unsubstituted phenyl.
Suitably, R1 is hydrogen, C1- alkyl, optionally substituted phenyl or optionally substituted heteroaryl. Preferably R1 is optionally substituted phenyl; most preferably unsubstituted phenyl.
Suitably, Y is oxygen or sulphur; preferably Y is oxygen.
Suitably, n is 4 to 12; preferably n is 4 to 8, most preferably n is 6 or 7.
Suitably, X is 5-tetrazolyl, S03H, P(0) (0R)2, P(0) (OH)2 or P(0) (R) (OR) in which R is hydrogen or c1-_4alkyl. Preferably X is S03H.
Suitable substituents for phenyl groups Ar and R1 include, for example, 1-3 groups which may be the same or different and are selected from 1_4alkyl, haloC1_4alkyl such as CF3, halogen, hydroxy and C1_4alkoxy.
Suitable heteroaryl groups include, for example, saturated or unsaturated 5- or 6-membered rings comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur.
Preferred such rings include, for example, thienyl and furyl rings.
Particularly preferred compounds of structure (I) include: sodium 6-(1,4,5-triphenylimidazol-2-yloxy)hexane- sulphonate; sodium 7-(l,4,5-triphenylimidazol-2-yloxy)heptane- sulphonate; 7-(1,4,5-triphenylimidazol-2-yloxy)heptanemethyl- phosphinate; and 7-(1,4 ,5-triphenylimidazol-2-yloxy)heptanephosphonate. The compounds of structure (I) can be prepared using procedures analogous to those known in the art. The present invention therefore provides in a further aspect a process for the preparation of compounds of structure (I) in which X is other than 5-tetrazolyl which comprises reaction of a compound of structure (II) :
Figure imgf000005_0001
in which
.Ar, R1, Y and n are as described for structure (I) and L is a leaving group, with a suitable source of the group X; and optionally thereafter forming a pharmaceutically acceptable salt thereof.
Compounds of structure (I) in which X is 5-tetrazolyl, can be prepared from compounds of structure (II) by standard techniques, for example, when L is bromine, by reaction with sodium cyanide in a suitable solvent such as dimethylsulphoxide , to form the intermediate compound in which L is cyano; followed by reaction with tri-n-butyl tin azide in, for example, tetrahydrofuran to form the desired compound of structure (I) .
Suitable leaving groups L will be apparent to those skilled in the art and include, for example, halogen, such as bromine.
Suitable sources of the group X will again be apparent to those skilled in the art and include, for example, where X is S03Na, sodium sulphite. The reaction between the compounds of structure (II) and the source of X is carried out in a solvent at elevated temperature. Preferably, for example where X is S03Na the reaction is carried out in aqueous ethanol at reflux temperature for a suitable period to allow the reaction to go to completion; and where X is a phosphorus containing group the reaction is carried out in an organic solvent such as toluene or xylene.
The compounds of structure (II) can be prepared from compounds of structure (III) :
Figure imgf000006_0001
in which Ar, Y and R1 are as described for structure (I) by reaction with, for example, a compound of formula L1(CH2)nL, in which L and L1 are suitable leaving groups, in the presence of a base such as potassium carbonate and a suitable solvent such as butanone. Suitable groups L are as described for structure (II) . Suitable groups L1 will be apparent to those skilled in the art, and include halogen, in particular bromine.
Compounds of structure (III) are known or can be prepared by standard techniques.
The compounds of structure (I) and their pharmaceutically acceptable salts have been found to be PGI2 agonists and as such are useful in therapy for the treatment of disease conditions in which such an effect is beneficial. More specifically, the compounds are expected to have utility as antithrombotic, vasodilatory, anti- atherosclerotic, antiinflammatory and cytoprotective agents. In particular, as antithrombotic and vasodilatory agents, the compounds are expected to be useful in the treatment of cardiovascular occlusive disorders including spasmodic and thrombotic disorders; coronary heart disease (primary and secondary prevention) ; stroke; post-operative thrombosis utilisation including post-angioplasty; deep vein thrombosis; peripheral vascular disease and Reynaud's disease. As antiathero- sclerotic agents the compounds would be expected to reduce atherosclerotic plaque formation; and as cytoprotective agents the compounds would be expected to protect liver and gastric mucosa, protect against mucosal and ulcerative damage and reduce infarct size in myocardial infarct.
In addition to the foregoing utilities the compounds have antihyperlipidaemic properties and as such are expected to be of use as lipid lowering agents, and in the treatment of atherosclerosis and its sequelae.
In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The compounds of structure (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s) , for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. A typical suppository formulation comprises a compound of structure (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
Preferably the composition is in unit dose form such as a tablet or capsule.
Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
The present invention also provides a method of mimicking the effects of PGI2 which comprises administering to a mammal in need thereof an effective amount of a compound of the structure (I) or a pharmaceutically acceptable salt thereof; and a method of treatment of cardiovascular disorders which comprises administering to a mammal in need thereof an effective amount of a compound of the structure (I) or a pharmaceutically acceptable salt thereof.
The pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen. For an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous , or intramuscular dose of between 0.1 mg and 100 g, preferably between 0.1 mg and 25 mg, of the compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.
The following Examples serve to illustrate the invention. Temperatures are recorded in degrees centigrade.
EXAMPLE 1
Sodium 6- (1.4.5-triphenylimidazol-2-yloxy)hexanesulphonate
A mixture of l,4,5-triphenylimidazol-2-one (6.25g), dibromohexane (24.4g) and potassium carbonate (5.53g) in dry butanone (300ml) was heated at reflux temperature for 24 hours. The mixture was cooled and the filtrate evaporated to an oil which was chromatographed on silica gel (hexane/ethyl acetate) to give l,4,5-triphenyl-2-(6- bromohexyloxy)imidazole (2.8g, 29%) as a white solid, m.p. 87-9°C.
NMR 5 (CDC13) 1.3-1.9 (8H, m, 5 X CH2) , 3.4 (2H, t, -CH2Br) , 4.5 (2H, t, -CH20) , 7.0-7.6 (15H, m, 3 X pH) ppm.
l,4,5-Triphenyl-2-(6-bromohexyloxy)imidazole (0.95g) was dissolved in hot ethanol (5ml) and a solution of sodium sulphite (0.25g) in hot water (3ml) was added. The white suspension was heated at reflux for 24 hours then evaporated to dryness. The residue was recrystallised from ethanol then methanol/ethanol to give sodium 6-(1,4,5-triphenylimidazol-2-yloxy)hexane¬ sulphonate (0.15g, 15%) as a colourless solid, m.p. 265°C. Found: C, 64.22; H, 5.51; N, 5.32; S, 6.24% C27H27N2Na04S + 1.2% H20 + 0.5% EtOH
Requires: C, 64.20; H, 5.57; N, 5.52; S, 6.32%.
EXAMPLE 2
Sodium 7- (1.4.5-triphenylimidazol-2-yloxy)heptane- sulphonate
A mixture of l,4,5-triphenylimidazol-2-one (15.3g) , dibromoheptane (50.6g) and potassium carbonate (13.8g) was heated at reflux temperature in dry butanone (750ml) for 20 hours. The mixture was cooled, filtered and the filtrate evaporated to an oil which was chromatographed on silica gel (hexane/ethyl acetate) to give 1,4,5- triphenyl-2-(7-bromoheptyloxy)imidazole (5.0g, 21%) as a white solid, m.p. 97-9βC.
NMR δ (CDC13) 1.3-1.9 (10H, m, 5 x CH2) , 3.4 (2H, t, -CH2Br) , 4.5 (2H, t, -CH20) , 7.0-7.6 (15H, m, 3 X Ph) ppm.
A solution of 1,4,5-triphenyl-2-(7-bromoheptyloxy)- imidazole (2.0g) in ethanol (10ml) was refluxed with a solution of sodium sulphite (0.55g) in water (5ml) for 20 hours. More sodium sulphite (0.2g) in water (1ml) was added and refluxed a further 20 hours. The mixture was evaporated to dryness, boiling ethanol added and filtered hot. Chromatography of the filtrate on silica gel (dichloromethane/methanol 5:1) followed by crystallisation from ethanol/isopropanol gave sodium 7-(1,4,5-triphenylimidazol-2-yloxy)heptanesulphonate (0.3g, 15%) as a colourless solid, m.p. 246-8°C. Found: C, 64.47; H, 5.85; N, 5.09; S, 5.50% 28 H29N2Na04s + 2 isopropanol + 2% water Requires: C, 64.19; H, 5.96; N, 5.25; S, 6.01%.
EXAMPLE 3
Ethyl 7- (1.4,5-triphenylimidazol-2-yloxy)heptanemethyl- phosphinate
A solution of l,4,5-triphenyl-2-(7-bromoheptyloxy)- imidazole (1.75g) and diethyl methylphosphonite (2.45g) in toluene (10 ml) was heated at reflux temperature for 48 hours. Methanol and water were added and the mixture evaporated to an oil. This was chromatographed on silica gel (ethyl acetate/ethanol) . The resulting oil slowly crystallised and was triturated with ether/petroleum ether, filtered then recrystallised from ethanol/ether to give ethyl 7-(1,4,5-triphenylimidazol-2-yloxy)heptane- methylphosphinate (1.06g, 57%) as a white solid, m.p. 101-2°C. Found: C, 72.05; H, 7.26; N, 5.52%
C31H37N2°3P
Requires: C, 72.07; H, 7.22; N, 5.42%.
EXAMPLE 4
Diethyl 7-(1.4.5-triphenylimidazol-2-yloxy)heptane- phosphonate
A mixture of 1,4,5-triphenyl-3-(7-bromoheptyl)- imidazol-2-one (l.Og) and triethyl phosphite (1.66g) was heated at reflux temperature in xylene (5 ml) for 40 hours. The solution was evaporated to an oil and re-evaporated from ethanol. The oil was partitioned between ether and water, the ether solution was separated, dried over magnesium sulphate and evaporated to an oil which was chromatographed on silica gel (ethyl acetate) to give diethyl 7-(l,4,5-triphenylimidazol-2-yl- oxy)heptanephosphonate as an oil which solidified on standing to a white solid (0.83g; 75%), m.p. 76-7°C. Found: C, 70.49; H, 7.40; N, 4.94%
C32H39N2°4P
Requires: C, 70.31; H, 7.19; N, 5.12%.
BIOLOGICAL DATA
METHOD FOR MEASUREMENT OF AGGREGATION OF WASHED HUMAN PLATELETS
Platelets were prepared from freshly drawn human blood. Blood was collected into acid citrate anticoagulant, centrifuged (5 min at 500g) , and the upper layer of platelet-rich plasma was removed. This platelet-rich plasma was incubated with aspirin (lOOuM) for 10 min at 37°C and then centrifuged (15 min at 200g) . The platelet pellet was resuspended (at approx. 1.5 x 108 cells/ml) in medium containing NaCl (145mM) , KC1 (5mM) , MgCl2 (lmM), CaCl2 (0.2mM), Hepes (lOmM, pH 7.4 at 37°C) , glucose (lOmM) , apyrase (lOμg/ml) . Aggregation was monitored (as a change in optical density) at 37°C in a 4 channel aggregometer (PAP-4 from Biodata Corp.). Fibrinogen (lmg/ml) and CaCl2 (lmM) were added to aliquots of platelets that were continuously stirred. The test compound (or 0.1% DMSO vehicle) was added 2 min before the aggregatory stimulus (lμM U46619) . The extent of aggregation was assessed 4 min after addition of the stimulus, and was calculated as % of the control response in the absence of test compound. Dose-response curves were constructed for measurement of IC50 values for each compound.
METHOD FOR MEASUREMENT OF j FOR INHIBITION OF [3H]ILOPROST BINDING TO HUMAN PLATELET MEMBRANES
Membranes were prepared from outdated platelet-rich plasma concentrates obtained from the Blood Transfusion Service. The platelets were homogenised in buffer containing Tris-Cl (5mM, pH 7.4 at 20°C) and EDTA (0.25mM), and then centrifuged (10 min at 26,000g). The membrane pellet was washed twice by homogenisation in buffer containing Tris-Cl (50mM, pH 7.4 at 20°C) and EDTA (0.25 mM) , followed by centrifugation. For measurement of [3H]iloprost binding, membranes (0.4-0.8mg) were incubated in the presence of Tris-Cl (50mM, pH 7.4 at 20°C) , MgCl2 (4mM) , EDTA (40μM) , [3H]iloprost (10nM) , DMSO (1.85%), and varying concentrations of the test compounds. For determination of non-specific binding, 20μM iloprost was included. The tubes (triplicates for each condition) were set up on ice, and then incubated for 30 min at 37°C. The incubations were terminated by rapid filtration on Whatman GF/B filters using a Brandel Harvester. The filters were washed and then counted for radioactivity. The K^ of the test compounds for inhibition of binding of [3H]iloprost to human platelet membranes was calculated from the IC50 for displacement of [3H]iloprost binding.
RESULTS
Figure imgf000015_0001

Claims

Claims :
1. A compound of structure (I):
Figure imgf000016_0001
in which each group Ar is the same or different and is optionally substituted phenyl or optionally substituted heteroaryl; R1 is hydrogen, C1_4alkyl, optionally substituted phenyl or optionally substituted heteroaryl; Y is oxygen or sulphur; n is 4 to 12; and X is 5-tetrazolyl, S03H, P(O) (0R)2, P(0)(0H)2, or
P(0) (R) (OR) in which R is hydrogen or C1_4alkyl, or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 in which each group Ar is phenyl, R1 is phenyl, Y is oxygen and X is
S03H.
3. A compound according to claim 2 in which n is 6 or 7.
4. A process for preparing a compound according to claim 1 in which X is other than 5-tetrazolyl which comprises reaction of a compound of structure (II) :
Figure imgf000016_0002
in which
Ar, R1, Y and n are as described for structure (I) and L is a leaving group, with a suitable source of the group X; and optionally thereafter forming a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.
6. A compound according to claim 1 for use in therapy.
PCT/GB1991/001544 1990-09-11 1991-09-10 Imidazole derivatives, their preparation and pharmaceutical compositions WO1992004332A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9019838.3 1990-09-11
GB909019838A GB9019838D0 (en) 1990-09-11 1990-09-11 Compounds

Publications (1)

Publication Number Publication Date
WO1992004332A1 true WO1992004332A1 (en) 1992-03-19

Family

ID=10682013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/001544 WO1992004332A1 (en) 1990-09-11 1991-09-10 Imidazole derivatives, their preparation and pharmaceutical compositions

Country Status (5)

Country Link
EP (1) EP0548168A1 (en)
JP (1) JPH06500789A (en)
AU (1) AU8528091A (en)
GB (1) GB9019838D0 (en)
WO (1) WO1992004332A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) * 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
EP0019688A1 (en) * 1977-07-07 1980-12-10 Ciba-Geigy Ag Diaza compounds and process for their preparation
EP0104342A1 (en) * 1982-07-29 1984-04-04 A. Nattermann & Cie. GmbH Triphenylimidazolyloxyalcanoic acids and their derivatives, process for their preparation and pharmaceutical compositions containing them
EP0130526A1 (en) * 1983-07-02 1985-01-09 A. Nattermann & Cie. GmbH Imidazol-2-yl mercapto alkanoic acids, process for producing the same and pharmaceutical preparations containing the same
EP0359197A1 (en) * 1988-09-14 1990-03-21 The Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 4,5-diaryl-2-substituted thioimidazoles
WO1991009021A1 (en) * 1989-12-11 1991-06-27 Rhone-Poulenc Sante Imidazoles
WO1991010662A1 (en) * 1990-01-12 1991-07-25 Rhone-Poulenc Rorer S.A. 2-substituted 4,5-diphenyl-imidazoles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) * 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
EP0019688A1 (en) * 1977-07-07 1980-12-10 Ciba-Geigy Ag Diaza compounds and process for their preparation
EP0104342A1 (en) * 1982-07-29 1984-04-04 A. Nattermann & Cie. GmbH Triphenylimidazolyloxyalcanoic acids and their derivatives, process for their preparation and pharmaceutical compositions containing them
EP0130526A1 (en) * 1983-07-02 1985-01-09 A. Nattermann & Cie. GmbH Imidazol-2-yl mercapto alkanoic acids, process for producing the same and pharmaceutical preparations containing the same
EP0359197A1 (en) * 1988-09-14 1990-03-21 The Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 4,5-diaryl-2-substituted thioimidazoles
WO1991009021A1 (en) * 1989-12-11 1991-06-27 Rhone-Poulenc Sante Imidazoles
WO1991010662A1 (en) * 1990-01-12 1991-07-25 Rhone-Poulenc Rorer S.A. 2-substituted 4,5-diphenyl-imidazoles

Also Published As

Publication number Publication date
JPH06500789A (en) 1994-01-27
EP0548168A1 (en) 1993-06-30
AU8528091A (en) 1992-03-30
GB9019838D0 (en) 1990-10-24

Similar Documents

Publication Publication Date Title
EP0233284A1 (en) Pharmacological compounds.
KR100291112B1 (en) Coenzyme-independent transacylase and platelet activator inhibitors
EP0535081A1 (en) Substituted benzimidazoles, process for their preparation and their pharmaceutical use
JPH0336834B2 (en)
AU4817690A (en) Therapeutically active substituted benzimidazole and process for its preparation
KR840001552B1 (en) Process for the preparation of cyclohexene derivatives
EP0548227A1 (en) Compounds
JPH09504557A (en) Novel dialkoxy-pyridinyl-benzimidazole derivatives
EP0178261A2 (en) Substituted 2-furanyl or 5-oxo-2-furanyl-alkoxy phosphoryl alkyl cyclimmonium salts
EP0181846A1 (en) New substituted benzimidazoles, a process for their preparation and their use for inhibiting gastric acid secretion
US5134151A (en) 2-picolylamine derivatives
US5338752A (en) Substituted 2-imidazolone derivatives, their preparation and pharmaceutical compositions
WO1992004330A1 (en) Substituted imidazoles, their preparation and pharmaceutical compositions
JPS6258335B2 (en)
AU665043B2 (en) Substituted benzimidazoles, process for their preparation as well as their use
WO1992004332A1 (en) Imidazole derivatives, their preparation and pharmaceutical compositions
US4138407A (en) 2,4 Pyrrolidinediones
US4447607A (en) Dibenzo diazacines
US4551470A (en) Hexahydro-3,5-dioxo-1H-pyrrolizine-2-carboxylic acid and derivatives, and use for reversing electroconvulsive shock amnesia
US4333948A (en) Pharmaceutical formulations containing prostaglandin
US4117232A (en) Transient pro-drug forms of phenylbutazone
US4036845A (en) Novel transient acyl derivatives of phenylbutazone
US4921865A (en) Aminoacylates of glycerol acetal
US4548936A (en) Δ1 -Pyrroline thiolactim ethers and a process for their preparation
US5663053A (en) Inhibition of inflammatory lipid mediators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991916250

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991916250

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1991916250

Country of ref document: EP